Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 6/20 | 0.32 |
| ▸ | JAK2 | O60674 | 4/20 | 0.32 |
| ▸ | JAK1 | P23458 | 4/20 | 0.32 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28605339 | 0.93 | TTK (0.33) | IGF1RPTK6TTKJAK2JAK1 | |
| SCHEMBL30171828 | 0.90 | CDK2 (0.34) | IGF1RPTK6TTKJAK2JAK1 | |
| SCHEMBL22124715 | 0.90 | CDK2 (0.34) | IGF1RPTK6TTKJAK2JAK1 | |
| SCHEMBL22124697 | 0.89 | CDK2 (0.34) | IGF1RPTK6TTKJAK2JAK1 | |
| SCHEMBL22125217 | 0.86 | TTK (0.34) | PTK6TTKJAK2JAK1MAPKAPK5 | |
| SCHEMBL24870944 | 0.86 | TTK (0.35) | PTK6TTKJAK2JAK1MAPKAPK5 | |
| SCHEMBL30171653 | 0.86 | TTK (0.35) | PTK6TTKJAK2JAK1MAPKAPK5 | |
| SCHEMBL22124792 | 0.85 | MAPKAPK5 (0.34) | PTK6TTKJAK2JAK1MAPKAPK5 | |
| SCHEMBL22123325 | 0.85 | PTK6 (0.38) | PTK6TTKJAK2JAK1MAPKAPK5 | |
| SCHEMBL30385313 | 0.85 | PTK6 (0.38) | PTK6TTKJAK2JAK1MAPKAPK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113195497-A | Novel imidazopyrazine derivatives | 豪夫迈·罗氏有限公司 | 2021-07-30 | — | — | CN | claimed |
| CN-113195497-A | Novel imidazopyrazine derivatives | 豪夫迈·罗氏有限公司 | 2021-07-30 | — | — | CN | disclosed |